CD40 and rheumatoid arthritis: Blocking the interaction between CD40/CD40L, using genetic or pharmacological (i.e., monoclonal antibody) means, has been implicated in various autoimmune diseases such as rheumatoid arthritis (Karnell et al., 2019).